OraSure Technologies, Inc. (NASDAQ:OSUR) Shares Bought by Walleye Capital LLC

Walleye Capital LLC raised its holdings in shares of OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report) by 50.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 294,547 shares of the medical instruments supplier's stock after purchasing an additional 99,095 shares during the quarter. Walleye Capital LLC owned 0.39% of OraSure Technologies worth $1,063,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in OSUR. Causeway Capital Management LLC purchased a new stake in OraSure Technologies during the fourth quarter valued at approximately $36,000. Raymond James Financial Inc. purchased a new position in OraSure Technologies during the fourth quarter valued at approximately $37,000. AXQ Capital LP purchased a new position in shares of OraSure Technologies in the 4th quarter valued at $51,000. RPO LLC bought a new position in shares of OraSure Technologies in the 4th quarter worth $56,000. Finally, US Bancorp DE boosted its position in OraSure Technologies by 310.4% during the fourth quarter. US Bancorp DE now owns 19,433 shares of the medical instruments supplier's stock valued at $70,000 after purchasing an additional 14,698 shares in the last quarter. 93.50% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, StockNews.com cut shares of OraSure Technologies from a "buy" rating to a "hold" rating in a report on Tuesday, March 4th.

OraSure Technologies Trading Down 1.5 %

Shares of NASDAQ OSUR traded down $0.05 during trading on Friday, reaching $2.99. 78,248 shares of the company traded hands, compared to its average volume of 871,671. The firm's fifty day simple moving average is $3.33 and its 200 day simple moving average is $3.71. The stock has a market cap of $223.28 million, a P/E ratio of 19.90 and a beta of 0.76. OraSure Technologies, Inc. has a 12-month low of $2.69 and a 12-month high of $5.59.

OraSure Technologies declared that its board has authorized a stock buyback program on Monday, March 24th that allows the company to repurchase $40.00 million in outstanding shares. This repurchase authorization allows the medical instruments supplier to repurchase up to 15.6% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company's management believes its stock is undervalued.

Insider Activity

In other news, CFO Kenneth J. Mcgrath bought 64,000 shares of OraSure Technologies stock in a transaction on Thursday, February 27th. The stock was acquired at an average price of $3.15 per share, with a total value of $201,600.00. Following the completion of the acquisition, the chief financial officer now directly owns 371,013 shares of the company's stock, valued at $1,168,690.95. The trade was a 20.85 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director John P. Kenny purchased 47,659 shares of the company's stock in a transaction that occurred on Thursday, February 27th. The shares were purchased at an average price of $3.17 per share, with a total value of $151,079.03. Following the completion of the transaction, the director now directly owns 70,915 shares of the company's stock, valued at $224,800.55. This represents a 204.93 % increase in their position. The disclosure for this purchase can be found here. Insiders bought a total of 190,284 shares of company stock valued at $600,348 in the last three months. 3.90% of the stock is currently owned by corporate insiders.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.